The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Real-world INSIGHT for myeloma
Saad Usmani, MD, FACP, Levine Cancer Institute, Charlotte, NC, discusses the INSIGHT MM study (NCT02761187), the largest prospective, observational study in multiple myeloma (MM) to date, following approximately 4,200 patients from 15 countries. Here he discusses the analysis of randomized controlled trials eligibility, with a focus on the treatment of frail MM patients in the real world. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
